InnoCare Pharma (HKSE:09969) ROCE %

: -12.08% (As of Jun. 2022)

View and export this data going back to 2020. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. InnoCare Pharma's annualized ROCE % for the quarter that ended in Jun. 2022 was -12.08%.

InnoCare Pharma ROCE % Historical Data

The historical data trend for InnoCare Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

ROCE %

-17,043.19

-51.86

-91.01

-11.45

-0.31

InnoCare Pharma Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
ROCE %					-18.39	-2.44	-7.59	5.64	-12.08

InnoCare Pharma ROCE % Calculation

InnoCare Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	-21.402465106056	/	( ( (5379.1497788754 - 123.82200093282)	+	(9058.0353051356 - 403.2195528551) )	/ 2 )
	=	-21.402465106056	/	( (5255.3277779426	+	8654.8157522805)	/ 2 )
	=	-21.402465106056	/	6955.0717651115
	=	-0.31 %

InnoCare Pharma's ROCE % of for the quarter that ended in Jun. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2022 )		(Q: Dec. 2021 )		(Q: Jun. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2022 )		(Q: Dec. 2021 )		(Q: Jun. 2022 )
	=	-1041.8847417553	/	( ( (9058.0353051356 - 403.2195528551)	+	(8956.490567063 - 356.74556486737) )	/ 2 )
	=	-1041.8847417553	/	( ( 8654.8157522805	+	8599.7450021956 )	/ 2 )
	=	-1041.8847417553	/	8627.280377238
	=	-12.08 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2022) EBIT data.

InnoCare Pharma (HKSE:09969) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

InnoCare Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (HKSE:09969) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » ROCE %

Traded in Other Exchanges

33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 100084

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. Its commercial drug candidate is Orelabrutinib and clinical-stage drug candidates are ICP-192, ICP-105, ICP-723, and others.

InnoCare Pharma (HKSE:09969) Headlines

No Headlines